secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001104659-23-009552
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q4 GAAP EPS $1.18, revenue $13.8B; guides FY2023 non-GAAP EPS $6.80-$6.95
-------------------------------------------------------------------------------

- Q4 2022 GAAP EPS $1.18 (down 22% YoY); non-GAAP EPS $1.62 (down 10%); revenue $13.8B (+2%, +8% ex-FX).
- Full-year 2022 sales $59.3B (+22% YoY); KEYTRUDA $20.9B (+22%); GARDASIL $6.9B (+22%).
- FY2023 guidance: sales $57.2B-$58.7B (incl. ~$1B LAGEVRIO); GAAP EPS $5.86-$6.01; non-GAAP EPS $6.80-$6.95.
- Completed Imago BioSciences acquisition for $1.35B; new ADC collaboration with Kelun-Biotech.
- Regulatory: KEYTRUDA approved for adjuvant NSCLC; positive KEYNOTE-859 (gastric) and KEYNOTE-966 (biliary) data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/0001104659-23-009552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465923009552/tm235007d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-009552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer